Sandbox: HCL therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(42 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Overview==
<br>
==Medical Therapy==
{{familytree/start |summary=PE diagnosis Algorithm.}}
* The mainstay of therapy for hairy cell leukemia patients is chemotherapy.
{{familytree | | | | | | A02 | | | | | |A02=<div style="width: 10em; padding:0.2em;">'''Initial patients evaluation'''</div>}}
* Asymptomatic hairy cell leukemia patients, with no indications for therapy, may be managed by observation and close follow-up.  
{{familytree|boxstyle= border-top: 0px;| | | | | | A01 | | | | | | |A01=<div style="width: 15em; padding:1em;text-align:center">History<br>Physical examination<br>Complete blood count</div>}}
* Indications to initiate medical therapy among patients with hairy cell leukemia include:
{{familytree | | | | | | |!| | | | | | | | | | | | }}
:* The presence of systemic symptoms such as fever, night sweats, and significant weight loss
{{familytree | | | | | | |!| | | | | | | | | | | | }}
:* The presence of subcostal abdominal discomfort due splenic distension
{{familytree | | | | |,|-|^|-|.| | | | | | }}
:* Positive history of recurrent infections.
{{familytree | | | | B02 | |B01| | |B02=<div style="width: 10em; padding:1em;text-align:center">'''Asymptomatic patients with no therapeutic indications'''</div>|B01=<div style="width: 15em; padding:1em;text-align:center">'''Symptomatic patients or evidence of therapeutic indications '''</div>}}
:* Hemoglobin concentration lower than 12 g/dl
{{familytree | | | | |!| | | |!| | | | }}
:* Platelets count lower than 100,000/mcl
{{familytree | | | | |!| | | |!| | | | }}
:* Absolute neutrophil count lower than 1000/mcl
{{familytree | | | | C02 | | C01| | |C01=<div style="width: 10em; padding:1em;">
* Pharmacological agents used for the treatment of hairy cell leukemia patients include:
'''[[Cladribine]]'''<br>
:* [[Cladribine]]
'''[[Pentostatin]]'''</div>|C02=<div style="width: 15em; padding:1em;text-align:center">'''Patients managed by observation and close follow-up'''</div>}}
:* [[Pentostatin]]
{{familytree | | | | | | | | |!| | | | | | | | | | | | | }}
:* [[Rituximab]]  
{{familytree | | | | | | |,|-|^|-|.| | | | | | | | | | | }}
:* [[Interferon alpha]]
{{familytree | | | | | | D02 | | D01 | | | | | | | | | |D01=<div style="width: 15em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|D02=<div style="width: 15em; padding:1em;text-align:center">'''Complete response'''</div>}}
:* [[Vemurafenib]]
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
* The preferred drug for the initial treatment of hairy cell leukemia could be either [[cladribine]] or [[pentostatin]].
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
* Hairy cell leukemia patients who demonstrate a complete response after initial medical therapy should be managed by follow-up and close observation for any signs of relapse.
{{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:center">
* A complete response for therapy among patients with hairy cell leukemia is defined by the following criteria:
'''[[Retuximab]] alone'''<br>
:* Absence of disease symptoms
'''[[Interferon alpha]] alone'''<br>
:* Absence of [[splenomegaly]] on physical exam
'''Alternative purine analogue {{withorwithout}} rituximab'''</div>|E02=<div style="width: 13em; padding:1em;text-align:center">'''Follow-up and close observation'''</div>}}
:* Recovery of the patients blood counts to the normal limits
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
:* Absence of malignant leukemic cells on blood smear or bone marrow aspiration
{{familytree | | | | | | |!| | | |!| | | | | | | | | | | }}
{{familytree | | | | | | E02 | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:center">'''No evidence of complete response'''</div>|E02=<div style="width: 13em; padding:1em;">
'''Relapse after one year: same initial purine analogue ± rituximab'''<br>
'''Relapse before one year: alternative purine analogue ± rituximab'''</div>}}
{{familytree | | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="width: 17em; padding:1em;text-align:lef">'''[[Vemurafenib]]'''</div>}}
{{familytree/end}}
<br>

Latest revision as of 02:16, 30 October 2015


 
 
 
 
 
Initial patients evaluation
 
 
 
 
 
 
 
 
 
 
History
Physical examination
Complete blood count
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asymptomatic patients with no therapeutic indications
 
Symptomatic patients or evidence of therapeutic indications
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients managed by observation and close follow-up
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complete response
 
No evidence of complete response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Follow-up and close observation
 

Retuximab alone
Interferon alpha alone

Alternative purine analogue ± rituximab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Relapse after one year: same initial purine analogue ± rituximab

Relapse before one year: alternative purine analogue ± rituximab
 
No evidence of complete response
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:_HCL_therapy&oldid=1181223"